Pomanda estimates the enterprise value of SOLVONIS THERAPEUTICS PLC at £339.7k based on a Turnover of £587k and 0.58x industry multiple (adjusted for size and gross margin).
solvonis therapeutics plcEstimated Valuation
£0
Pomanda estimates the enterprise value of SOLVONIS THERAPEUTICS PLC at £0 based on an EBITDA of £-3m and a 3.96x industry multiple (adjusted for size and gross margin).
solvonis therapeutics plcEstimated Valuation
£4.5m
Pomanda estimates the enterprise value of SOLVONIS THERAPEUTICS PLC at £4.5m based on Net Assets of £2m and 2.24x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Solvonis Therapeutics PlcOverview
Solvonis Therapeutics Plc is a live company located in london, SW1W 9NF with a Companies House number of 10776788. It operates in the other professional, scientific and technical activities n.e.c. sector, SIC Code 74909. Founded in May 2017, it's largest shareholder is
victor bolduev
with a 32.1% stake. Solvonis Therapeutics Plc is a young,
small sized company, Pomanda has estimated its turnover at
£587k with
rapid
growth in recent years.
Pomanda's financial health check has awarded Solvonis Therapeutics Plc a 3.5 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 6 areas for improvement. Company Health Check FAQs
Health Rating3.5out of 5
4 Strong
2 Regular
6 Weak
Size
annual sales of £587k, make it smaller than the average company (£2.9m)
£587k - Solvonis Therapeutics Plc
£2.9m - Industry AVG
Growth
3 year (CAGR) sales growth of 140%, show it is growing at a faster rate (7.2%)
140% - Solvonis Therapeutics Plc
7.2% - Industry AVG
Production
with a gross margin of 44%, this company has a comparable cost of product (44.9%)
44% - Solvonis Therapeutics Plc
44.9% - Industry AVG
Profitability
an operating margin of -531% make it less profitable than the average company (5.6%)
-531% - Solvonis Therapeutics Plc
5.6% - Industry AVG
Employees
with 7 employees, this is below the industry average (23)
7 - Solvonis Therapeutics Plc
23 - Industry AVG
Pay Structure
on an average salary of £136.9k, the company has a higher pay structure (£53.9k)
£136.9k - Solvonis Therapeutics Plc
£53.9k - Industry AVG
Efficiency
resulting in sales per employee of £83.9k, this is less efficient (£125.2k)
£83.9k - Solvonis Therapeutics Plc
£125.2k - Industry AVG
Debtor Days
it gets paid by customers after 40 days, this is earlier than average (56 days)
40 days - Solvonis Therapeutics Plc
56 days - Industry AVG
Creditor Days
its suppliers are paid after 176 days, this is slower than average (31 days)
176 days - Solvonis Therapeutics Plc
31 days - Industry AVG
Stock Days
it holds stock equivalent to 56 days, this is more than average (30 days)
56 days - Solvonis Therapeutics Plc
30 days - Industry AVG
Cash Balance
has cash to cover current liabilities
for 23 weeks, this is average cash available to meet short term requirements (25 weeks)
23 weeks - Solvonis Therapeutics Plc
25 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 17.8%, this is a lower level of debt than the average (53.3%)
17.8% - Solvonis Therapeutics Plc
53.3% - Industry AVG
SOLVONIS THERAPEUTICS PLC financials
EXPORT
Solvonis Therapeutics Plc's latest turnover from December 2023 is £587 thousand and the company has net assets of £2 million. According to their latest financial statements, Solvonis Therapeutics Plc has 7 employees and maintains cash reserves of £187 thousand as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Dec 2023
Dec 2022
Dec 2021
May 2021
May 2020
May 2019
May 2018
Turnover
587,000
542,000
219,000
520,000
42,350
30,883
17,311
Other Income Or Grants
Cost Of Sales
329,000
242,000
118,000
30,000
23,310
16,463
9,310
Gross Profit
258,000
300,000
101,000
490,000
19,039
14,421
8,001
Admin Expenses
3,375,000
3,001,000
1,047,000
934,000
140,177
123,144
338,062
Operating Profit
-3,117,000
-2,701,000
-946,000
-444,000
-121,138
-108,723
-330,061
Interest Payable
3,000
4,000
8,000
7,000
25,259
11,549
Interest Receivable
15
1,131
687
Pre-Tax Profit
-3,120,000
-2,705,000
-954,000
-451,000
-146,383
-119,141
-329,374
Tax
Profit After Tax
-3,120,000
-2,705,000
-954,000
-451,000
-146,383
-119,141
-329,374
Dividends Paid
Retained Profit
-3,120,000
-2,705,000
-954,000
-451,000
-146,383
-119,141
-329,374
Employee Costs
958,000
1,273,000
206,000
304,000
43,142
44,576
43,495
Number Of Employees
7
9
6
6
1
1
1
EBITDA*
-3,009,000
-2,588,000
-900,000
-335,000
-121,138
-108,723
-330,061
* Earnings Before Interest, Tax, Depreciation and Amortisation
Dec 2023
Dec 2022
Dec 2021
May 2021
May 2020
May 2019
May 2018
Tangible Assets
13,000
687,000
322,000
376,000
Intangible Assets
2,107,000
2,095,000
2,068,000
2,068,000
2,067,750
2,067,750
2,067,750
Investments & Other
13,000
13,000
12,000
1,328,326
1,270,619
779,188
Debtors (Due After 1 year)
12,000
Total Fixed Assets
2,120,000
2,782,000
2,390,000
2,444,000
3,396,076
3,338,369
2,846,938
Stock & work in progress
51,000
187,000
Trade Debtors
65,000
35,000
20,000
43,000
Group Debtors
Misc Debtors
27,000
240,000
122,000
43,000
7,165
2,470
3,200
Cash
187,000
1,640,000
598,000
39,000
2,851
26,960
274,738
misc current assets
total current assets
346,000
2,157,000
740,000
125,000
10,016
29,430
277,938
total assets
2,466,000
4,939,000
3,130,000
2,569,000
3,406,092
3,367,799
3,124,876
Bank overdraft
958,000
654,000
Bank loan
Trade Creditors
159,000
185,000
841,000
420,000
6,441
5,873
3,000
Group/Directors Accounts
other short term finances
485,976
342,202
hp & lease commitments
12,000
4,000
other current liabilities
247,000
178,000
519,000
248,000
59,273
18,939
1,950
total current liabilities
418,000
367,000
2,318,000
1,322,000
551,690
367,014
4,950
loans
44,000
36,000
hp & lease commitments
22,000
18,000
Accruals and Deferred Income
other liabilities
provisions
total long term liabilities
22,000
18,000
total liabilities
440,000
385,000
2,318,000
1,322,000
551,690
367,014
4,950
net assets
2,026,000
4,554,000
812,000
1,247,000
2,854,402
3,000,785
3,119,926
total shareholders funds
2,026,000
4,554,000
812,000
1,247,000
2,854,402
3,000,785
3,119,926
Dec 2023
Dec 2022
Dec 2021
May 2021
May 2020
May 2019
May 2018
Operating Activities
Operating Profit
-3,117,000
-2,701,000
-946,000
-444,000
-121,138
-108,723
-330,061
Depreciation
108,000
113,000
46,000
109,000
Amortisation
Tax
Stock
-136,000
187,000
Debtors
-183,000
121,000
146,835
78,835
4,695
-730
3,200
Creditors
-26,000
-656,000
834,559
413,559
568
2,873
3,000
Accruals and Deferred Income
69,000
-341,000
459,727
188,727
40,334
16,989
1,950
Deferred Taxes & Provisions
Cash flow from operations
-2,647,000
-3,893,000
247,451
188,451
-84,931
-88,131
-328,311
Investing Activities
capital expenditure
554,000
-505,000
-368,250
-485,250
-2,067,750
Change in Investments
13,000
-1,328,326
-1,316,326
57,707
491,431
779,188
cash flow from investments
554,000
-518,000
960,076
831,076
-57,707
-491,431
-2,846,938
Financing Activities
Bank loans
Group/Directors Accounts
Other Short Term Loans
-485,976
-485,976
143,774
342,202
Long term loans
8,000
36,000
Hire Purchase and Lease Commitments
12,000
22,000
other long term liabilities
share issue
592,000
6,447,000
-1,088,402
-1,156,402
3,449,300
interest
-3,000
-4,000
-8,000
-7,000
-25,244
-10,418
687
cash flow from financing
609,000
6,501,000
-1,582,378
-1,649,378
118,530
331,784
3,449,987
cash and cash equivalents
cash
-1,453,000
1,042,000
595,149
36,149
-24,109
-247,778
274,738
overdraft
-958,000
958,000
654,000
change in cash
-1,453,000
2,000,000
-362,851
-617,851
-24,109
-247,778
274,738
solvonis therapeutics plc Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for solvonis therapeutics plc. Get real-time insights into solvonis therapeutics plc's credit score, group structure and payment trends.
Perform a competitor analysis for solvonis therapeutics plc by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other small companies, companies in SW1W area or any other competitors across 12 key performance metrics.
solvonis therapeutics plc Ownership
SOLVONIS THERAPEUTICS PLC group structure
Solvonis Therapeutics Plc has 2 subsidiary companies.
The largest shareholders in Solvonis Therapeutics Plc include Victor Bolduev and Adv. Shachar Shimony.
victor bolduev
32.14%
adv. shachar shimony
28.57%
alba capital pty ltd
10.71%
platypus investments limited
5.71%
robert neville chisholm eastman & elizabeth anne eastman a/t neville eastman family trust
2.86%
chitta lu limited
2.86%
s u f global limited
2.86%
brightght global limited
2.86%
the trust company (australia) limited
2.14%
blueknight corporation pty ltd
1.9%
solvonis therapeutics plc directors
Solvonis Therapeutics Plc currently has 4 directors.
The longest serving directors include
Mr Nicholas Nelson (Mar 2024) and
Mr Anthony Tennyson (May 2024).
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to solvonis therapeutics plc.
solvonis therapeutics plc Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for SOLVONIS THERAPEUTICS PLC. This can take several minutes, an email will notify you when this has completed.
solvonis therapeutics plcCompanies House Filings - See Documents
